Hikma Pharmaceuticals PLC (LON:HIK)
1,650.00
+6.00 (0.36%)
Nov 12, 2026, 4:35 PM GMT
Hikma Pharmaceuticals Revenue
Hikma Pharmaceuticals had revenue of $1.73B USD in the half year ending June 30, 2026, with 10.13% growth. This brings the company's total for the last twelve months to $3.42B, up 6.31% year-over-year. In the year 2025, Hikma Pharmaceuticals had annual revenue of $3.35B with 7.10% growth. That makes Hikma Pharmaceuticals the 3,490th largest company in the world by revenue and 113th in the United Kingdom.
Revenue (ttm)
$3.42B
Revenue Growth
+6.31%
P/S Ratio
1.33
Revenue / Employee
$359.89K
Employees
9,500
Market Cap
3.42B GBP
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Hikma Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.35B | 222.00M | 7.10% |
| Dec 31, 2024 | 3.13B | 252.00M | 8.77% |
| Dec 31, 2023 | 2.88B | 358.00M | 14.22% |
| Dec 31, 2022 | 2.52B | -36.00M | -1.41% |
| Dec 31, 2021 | 2.55B | 212.00M | 9.06% |
| Dec 31, 2020 | 2.34B | 134.00M | 6.07% |
| Dec 31, 2019 | 2.21B | 137.00M | 6.62% |
| Dec 31, 2018 | 2.07B | 134.00M | 6.92% |
| Dec 31, 2017 | 1.94B | -14.00M | -0.72% |
| Dec 31, 2016 | 1.95B | 510.00M | 35.42% |
| Dec 31, 2015 | 1.44B | -49.00M | -3.29% |
| Dec 31, 2014 | 1.49B | 124.00M | 9.08% |
| Dec 31, 2013 | 1.37B | 256.00M | 23.08% |
| Dec 31, 2012 | 1.11B | 190.98M | 20.80% |
| Dec 31, 2011 | 918.03M | 187.09M | 25.60% |
| Dec 31, 2010 | 730.94M | 94.05M | 14.77% |
| Dec 31, 2009 | 636.88M | 56.23M | 9.68% |
| Dec 31, 2008 | 580.66M | 131.86M | 29.38% |
| Dec 31, 2007 | 448.80M | 131.77M | 41.57% |
| Dec 31, 2006 | 317.02M | 54.81M | 20.90% |
| Dec 31, 2005 | 262.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Haleon | 11.15B |
| HUTCHMED (China) | 413.87M |
| ECO Animal Health Group | 87.53M |
| Allergy Therapeutics | 57.29M |
| Shield Therapeutics | 44.19M |
| Provexis | 1.26M |
| Chill Brands Group | 955.18K |
Hikma Pharmaceuticals News
- 7 days ago - Hikma Pharmaceuticals Raises Profit Floor as Branded Growth Offsets Injectables Slowdown - MarketBeat
- 7 days ago - Hikma Pharmaceuticals Transcript: Trading update - Transcripts
- 7 days ago - Hikma Pharmaceuticals Earnings release: Trading update - Filings
- 7 days ago - Hikma Raises Branded Growth Outlook, Narrows 2026 Profit Guidance - Nasdaq
- 7 days ago - UK's Hikma tightens annual profit outlook as branded medicines drive growth - Reuters
- 17 days ago - Hikma Pharmaceuticals PLC - Depositary Receipt Price Target Decreased by 17.53% to $51.72 - Nasdaq
- 23 days ago - Hikma Pharmaceuticals Spotlights R&D Shift, Nasal Epinephrine Filing Progress - MarketBeat
- 23 days ago - Hikma Pharmaceuticals Transcript: Investor update - Transcripts